Últimas investigaciones científicas sobre cáncer colorrectal
Copia esta URL y pégala en tu lector RSS favorito (Feedly, Inoreader, etc.)
https://crcwarriors.org/api/scientific-news.php?action=rss
The incidence of early-onset colorectal cancer (eoCRC) is rising, yet optimal management in the metastatic setting remains unclear. We characterized and compared treatment patterns among patients with early-onset and later-onset (loCRC) metastatic CRC, and evaluated outcomes by treatment regimen amo...
Colorectal cancer outcomes are heterogeneous, so greater prognostic discrimination is needed. In this retrospective real-world analysis, we assessed the prognostic effect of markers of systemic inflammation in a cohort of patients with RAS/BRAF wild-type metastatic colorectal cancer (mCRC) who recei...
A 63-year-old woman with microsatellite instability-high metastatic colorectal cancer experienced tumor enlargement and worsening general condition after the first dose of pembrolizumab. This was determined to represent true progression rather than pseudoprogression. Second-line treatment with fluor...
This study aims to present the diagnosis, treatment process, and clinical course of a patient with advanced rectal adenocarcinoma presenting with rare duodenal metastases. A 47-year-old male patient presented with constipation. A mass obstructing the entire lumen was detected in the rectosigmoid reg...
We previously generated a global bulk-level proteogenomic atlas of metastatic colorectal cancer (CRC) in a Chinese cohort (CCRC). Using formalin-fixed paraffin-embedded tissues from this cohort, we identified 2095 ectopic lymphoid-like structures (ELSs) across 132 primary tumors. Both lymphoid aggre...
Neoadjuvant chemotherapy for resectable colon cancer has emerged as a potential strategy to improve systemic treatment delivery, enhance tumor downstaging, and facilitate margin-negative resection in selected patients with locally advanced disease. However, its role remains controversial because rad...
Colorectal cancer (CRC) ranks as the third highest incidence among malignancies for human and the second most common cause of cancer-related mortality in the United States. Accumulating evidence has established microRNAs (miRNAs) as critical regulators of cancer development and therapeutic response....
High-dose vitamin C (HDVC) has emerged as a potential adjunct for cancer treatment because of its selective toxicity against malignant cells. When administered at pharmacological concentrations, it typically operates as a pro-oxidant, generating hydrogen peroxide, which predominantly targets cancer ...
Molecular heterogeneity of colorectal cancer (CRC) remains a major barrier to precision therapy. In this study, we integrated eight public aging-related resources to construct an aging-related gene set and performed network perturbation analysis on the TCGA CRC cohort using a Reactome-based referenc...
Peritoneal metastasis from colorectal cancer (pmCRC) is a major form of distant spread and generally confers a poor prognosis. This study aimed to evaluate its global research activity, hotspots, and emerging trends through a bibliometric analysis. We searched the Web of Science Core Collection, Pub...
Colorectal carcinoma (CRC) exerts a growing global disease burden, with microsatellite-stable/proficient mismatch repair (MSS/pMMR) tumors exhibiting intrinsic refractoriness to immune-checkpoint blockade (ICB) owing to low tumor mutational burden, limited neoantigenicity, and an immunosuppressive t...
Precision medicine is used to treat gastrointestinal malignancies including esophageal, gastric, small bowel, colorectal, and pancreatic cancers. Cutting-edge assays to detect and treat these cancers are active areas of research and will soon become standard of care. Colorectal cancer is a prime exa...
Ewing sarcoma is an undifferentiated small round cell sarcoma that most commonly presents as a malignant bone tumor in pediatric and young adult patients. The diagnosis is typically confirmed by molecular genetic identification of a fusion protein, most commonly involving members of the FET and ETS ...
The macromolecular monoclonal antibodies targeting CTLA-4/PD-1/PD-L1 have revolutionized cancer immunotherapy. However, their clinical efficacy is limited by poor tissue penetration, strong immunogenicity and frequent cytokine release syndrome (CRS) risk. In contrast, natural small molecules can eff...
HER2 amplification is demonstrated to influence response to therapy and outcomes in metastatic colorectal cancer (mCRC), but its role in resectable CRC remains unclear. This study investigated the prognostic impact of WES-defined ERBB2 amplification and its association with adjuvant chemotherapy (AC...
Systemic inflammation and insulin resistance are increasingly recognized as key determinants of perioperative vulnerability in patients with colorectal cancer. The Composite TyG-Inflammation Index (CTI), which integrates the triglyceride-glucose index and C-reactive protein, has recently emerged as ...
Immunotherapy has reshaped the treatment landscape of colorectal cancer (CRC), with the clearest and most durable benefit established in mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) disease. However, framing CRC immunotherapy simply as "MSI-H responsive versus microsatell...
Cancer has a substantial health and economic impact on the populations of the Gulf countries-the United Arab Emirates (UAE), Kuwait, and Oman; however, uncertainty remains among decision-makers, payers, and stakeholders regarding their clinical and economic advantages. Hence, this study aims to eval...
Colorectal cancer (CRC) carries a high recurrence risk. Aspirin has been proposed for secondary prevention, but its benefit remains uncertain. This systematic review and meta-analysis evaluated aspirin's impact on disease-free survival (DFS) and overall survival (OS). A systematic search of four dat...
The application of Multiple Instance Learning (MIL) for classifying Whole Slide Images (WSIs) has gained extensive use in recent years, primarily due to the high cost and time consumption associated with pixel-level annotation of WSIs, which is challenging to accomplish. The advancements in MIL for ...
Here, we establish a co-clinical computed tomography (CT) radiomics pipeline for the identification of candidate imaging biomarkers in RAS-mutant metastatic colorectal cancer (mCRC). Orthotopic KRAS-mutant xenograft models (LOVO-Luc2 (N = 52) and SW480-Luc2 (N = 52)) were treated with standard-o...
Ferroptosis is a regulated necrotic cell death pathway, which demonstrates significant anticancer potential. As the only ferroptosis-based nanomedicine under clinical trial evaluation, carbon nanoparticle-Fe (II) complex (CNSI-Fe) not only induces ferroptosis in tumor cells, but also serves as photo...
Dual-target c-Met/VEGFR kinase inhibitors have emerged as promising therapeutic agents for cancer therapy, although their underlying antitumor mechanisms remain poorly defined. In this study, we demonstrate that foretinib, a selective c-Met/VEGFR2 inhibitor, triggers immunogenic cell death (ICD) in ...
The addition of bevacizumab (BEV) to chemotherapy has shown survival benefits in metastatic colorectal cancer but may increase operative risks, potentially limiting applicability in cytoreductive surgery (CRS) for CRPM. We report the phase II BEV-IP trial investigating the feasibility, safety and po...
Early onset colorectal cancer, defined as colorectal malignancy occurring before age 50, has been rising globally. Increasing molecular evidence suggests that early onset colorectal cancer is not merely a premature form of late-onset colorectal cancer but a distinct biologic entity with unique genom...
Hepatic resection combined with systemic therapy represents the standard of care for colorectal liver metastases (CRLMs). Although parenchyma-sparing surgery prioritizes R0 resection and preserves liver function, the clinical relevance of minimal margins remains debated. At the same time, tumor biol...
To find the maximum tolerated dose (MTD) of yttrium-90 (90Y) glass microspheres, with drug-eluting beads preloaded with irinotecan (DEBIRI) in patients with colorectal liver metastases (CRLMs). In this prospective study, participants with bilobar, unresectable, liver-dominant CRLM progressing after ...
Rectal cancer remains a global health burden, with immunotherapy emerging as a transformative treatment modality demonstrating substantial pathological complete response rates across molecular subtypes. However, current response assessment methods based on anatomical size measurements (RECIST criter...
The Kirsten rat sarcoma viral oncogene homolog (KRAS) is defined as frequently mutated oncogenes in colorectal cancer. We aimed to clarify the clinical impact of KRAS mutation status on recurrence patterns, the surgical management of recurrent lesions, and prognostic outcomes after curative hepatect...
This study aims to investigate the association between baseline CT-derived body composition parameters and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) receiving immunotherapy, and to develop a personalized clinico-radiological prognostic model. We retrospecti...
Hydrogen (H2), a non-toxic therapeutic gas, exerts antitumor effects by disrupting intracellular redox homeostasis and inducing mitochondrial dysfunction. The high diffusibility of H2, as well as its storage difficulties, hinders its sustained release at tumor sites. Thus, the therapeutic effect rem...
Microsatellite instability (MSI) is a key prognostic biomarker in colorectal cancer (CRC), guiding immunotherapy planning. MSI testing requires invasive and costly tissue sampling. 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) offers noninvasive metabolic profi...
Chemotherapy response in colorectal cancer (CRC) exhibits significant heterogeneity, with current clinical predictors failing to capture complex genomic determinants of resistance. We developed a hybrid deep learning framework integrating convolutional neural networks (CNNs) and bidirectional long s...
Epidermal Growth Factor Receptor (EGFR) is crucial for cell proliferation and survival, and has emerged as a promising therapeutic target for colorectal cancer (CRC). Anti-EGFR monoclonal antibodies (mAbs) have demonstrated success in various clinical practice in CRC patients. However, they are only...
Colorectal carcinoma (CRC) is frequently typified by chronic inflammation and high levels of immunosuppression that render it resistant to immunotherapy. The multimodal immunostimulatory mechanisms of oncolytic virotherapy make it an attractive strategy for priming tumors for immune-checkpoint block...
Background: The optimal use of chemotherapy rechallenge in later-line metastatic colorectal cancer (mCRC) remains uncertain. We compared third-line FOLFOX plus bevacizumab rechallenge with regorafenib and examined whether the oxaliplatin-free interval was associated with treatment outcomes. Methods:...
From a molecular perspective, colorectal cancer is a heterogeneous disease in which microsatellite instability (MSI) phenotypes, mismatch repair (MMR) status, chromosomal instability, or mutations in BRAF, KRAS, NRAS, and TP53 can influence prognosis, hereditary cancer risk assessment, and therapeut...
Immune checkpoint blockade has changed the management of several digestive system cancers, but its impact is highly context dependent. This review evaluates evidence for esophageal, gastric and gastroesophageal junction, colorectal, hepatocellular, biliary tract and gallbladder, and pancreatic cance...
Immune checkpoint blockade produces durable benefit mainly in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) colorectal cancer (CRC), whereas most microsatellite-stable/mismatch repair-proficient (MSS/pMMR) tumors remain poorly inflamed and resistant to immunotherapy. This fo...
Colorectal cancer (CRC) remains a leading cause of cancer-related mortality worldwide, although advances in molecular profiling and artificial intelligence (AI) are now reshaping precision oncology in ways that promise better patient outcomes. This review synthesises contemporary evidence on next-ge...
Colonic intussusception is a rare cause of intestinal obstruction in adults, and is frequently associated with an underlying malignancy. Mucinous adenocarcinoma (MAC) is an uncommon histological subtype of colorectal cancer, characterized by abundant extracellular mucin and unfavorable biological be...
Brain metastases (BrM) are a major cause of cancer-related mortality. To successfully colonize the brain, cancer cells must acquire unique adaptations. We hypothesized that BrM, regardless of their primary tumor origin, share convergent molecular features enabling brain colonization while retaining ...
Colorectal cancer (CRC) is the third most common cancer worldwide, and its clinical management remains limited by systemic toxicity and drug resistance. Combination regimens can improve therapeutic efficacy through synergistic mechanisms, yet they remain constrained by the divergent physicochemical ...
Colorectal cancer (CRC) is closely associated with chronic inflammation, and the NF-κB pathway acts as a central regulator of the inflammatory response that promotes tumor progression. In this study, we examined the anticancer and anti-inflammatory potential of anilino-1,4-naphthoquinone derivative...
As the most prevalent subtype of colorectal cancer, microsatellite-stable colorectal cancer (MSS CRC) is resistant to T cell-focused immune checkpoint blockade due to its low mutational burden and immunosuppressive tumor microenvironment. Despite reprogramming tumor-associated macrophages toward a t...
5-Fluorouracil (5-FU)-based regimens are a cornerstone of colorectal cancer (CRC) chemotherapy. Levofloxacin (LVF), a widely used fluoroquinolone antibiotic, has been reported to exhibit anticancer properties. We investigated LVF's ability to enhance CRC chemosensitivity to 5-FU in cell lines, subcu...
Liquid biopsy guided anti-EGFR rechallenge therapy is gaining ground as a potential option for patient with refractory metastatic colorectal cancer. However, the identification of potential biomarkers to implement patient's stratification is required. The CAVE-2 GOIM trial investigated the role of r...
The BRAF V600E mutation in metastatic colorectal cancer (mCRC) is associated with a poor prognosis when treated with conventional chemotherapy regimens. Recent advances in research have shown promise in using combined BRAF inhibitor and an EGFR inhibitor to treat BRAF V600E-mutated mCRC, with intern...
Gastrointestinal (GI) cancers remain a leading cause of cancer-related morbidity and mortality worldwide despite major advances in systemic therapy. Although immune checkpoint inhibitors have improved outcomes in selected biomarker-defined populations, most GI malignancies, including microsatellite-...
Cancer persists as a significant global health burden, with conventional therapeutic approaches frequently constrained by drug resistance and disease relapse, underscoring the urgent requirement for innovative treatment modalities. Recent advances in regulated cell death have uncovered promising the...